- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00365378
Study of Human Papillomavirus (HPV) 16 Vaccine in the Prevention of HPV 16 Infection in 16- to 23-Year-Old Females (V501-005)
October 22, 2015 updated by: Merck Sharp & Dohme LLC
Study of Pilot Manufacturing Lot of HPV 16 Virus-Like Particle (VLP) Vaccine in the Prevention of HPV 16 Infection in 16- to 23-Year-Old Females
Subjects received HPV 16 L1 VLP vaccine or placebo (1:1 ratio).
Endpoints included efficacy, immunogenicity, and safety.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
2409
Phase
- Phase 2
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 23 years (Child, Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Healthy, unmarried females age 16 to 23 years with intact uteri
- Not pregnant at enrollment
- Agreed to use effective contraception through Month 7 of the study
- A lifetime history of 0 to 5 male partners with whom the subjects engaged in at least one episode of insertive intercourse
Exclusion Criteria:
- No prior history of Human Papillomavirus (HPV) vaccination
- No receipt of any other vaccination within 1 month prior to enrollment or plans to receive any other vaccination within 1 month prior to or after any dose of study vaccine
- No prior history of an abnormal Papanicolaou (Pap) test showing Squamous intraepithelial lesion (SIL) or biopsy showing Cervical intraepithelial neoplasia (CIN)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: 2
Placebo
|
A 0.5 intramuscular placebo injection given at Day 1, Month 2, and Month 6
|
Experimental: 1
HPV 16 L1 VLP vaccine
|
A 0.5 intramuscular injection given at Day 1, Month 2, and Month 6
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Persistent HPV 16 Infection
Time Frame: Through Month 48
|
Cases of persistent infection were those with detection of HPV 16 by PCR (Polymerase chain reaction) on at least 2 consecutive visits at least 4 months apart; or detection of HPV 16 in a cervical biopsy specimen showing pathologic evidence of CIN1 (Cervical intraepithelial neoplasia), CIN2 or CIN3 together with HPV 16 detected at the visit immediately before or after the biopsy; or detection of HPV 16 on a subject's last visit.
|
Through Month 48
|
Incidence of HPV 16-related CIN1, CIN2 or C1N3
Time Frame: Through Month 48
|
Cases of HPV 16-related CIN1, CIN2 or CIN3 are those with detection of HPV 16 in a cervical biopsy specimen showing pathologic evidence of CIN1, CIN2 or CIN3 together with HPV 16 detected at the visit immediately before or after the biopsy.
|
Through Month 48
|
Serum Anti-HPV 16 Geometric Mean Titers
Time Frame: Month 7
|
The limit of detection of the assay was 6 mMU/ml.
Samples with titer below the limit of detection were assigned a value of 3 for calculation of GMT and confidence interval.
GMTs and confidence limits below the limit of detection are shown as "6.0".
|
Month 7
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, Chiacchierini LM, Jansen KU; Proof of Principle Study Investigators. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med. 2002 Nov 21;347(21):1645-51. doi: 10.1056/NEJMoa020586.
- Barr E, Gause CK, Bautista OM, Railkar RA, Lupinacci LC, Insinga RP, Sings HL, Haupt RM. Impact of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine in a sexually active population of North American women. Am J Obstet Gynecol. 2008 Mar;198(3):261.e1-11. doi: 10.1016/j.ajog.2007.09.001.
- Ault KA; Future II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet. 2007 Jun 2;369(9576):1861-1868. doi: 10.1016/S0140-6736(07)60852-6.
- Mao C, Koutsky LA, Ault KA, Wheeler CM, Brown DR, Wiley DJ, Alvarez FB, Bautista OM, Jansen KU, Barr E. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol. 2006 Jan;107(1):18-27. doi: 10.1097/01.AOG.0000192397.41191.fb. Erratum In: Obstet Gynecol. 2006 Jun;107(6):1425.
- Paavonen J; Future II Study Group. Baseline demographic characteristics of subjects enrolled in international quadrivalent HPV (types 6/11/16/18) vaccine clinical trials. Curr Med Res Opin. 2008 Jun;24(6):1623-34. doi: 10.1185/03007990802068151. Epub 2008 Apr 23.
- Fraser C, Tomassini JE, Xi L, Golm G, Watson M, Giuliano AR, Barr E, Ault KA. Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine. Vaccine. 2007 May 22;25(21):4324-33. doi: 10.1016/j.vaccine.2007.02.069. Epub 2007 Mar 12.
- Wiley DJ, Masongsong EV, Lu S, Heather L S, Salem B, Giuliano AR, Ault KA, Haupt RM, Brown DR. Behavioral and sociodemographic risk factors for serological and DNA evidence of HPV6, 11, 16, 18 infections. Cancer Epidemiol. 2012 Jun;36(3):e183-9. doi: 10.1016/j.canep.2011.12.007. Epub 2012 Jan 25.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 1999
Primary Completion (Actual)
March 1, 2004
Study Completion (Actual)
July 1, 2009
Study Registration Dates
First Submitted
August 16, 2006
First Submitted That Met QC Criteria
August 16, 2006
First Posted (Estimate)
August 17, 2006
Study Record Updates
Last Update Posted (Estimate)
October 23, 2015
Last Update Submitted That Met QC Criteria
October 22, 2015
Last Verified
October 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- V501-005
- 2006_515
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HPV 16 Infection
-
Lee's Pharmaceutical LimitedUnknownCervical HPV-16 and / or HPV-18 InfectionChina
-
Gilead SciencesTerminatedHuman Papillomavirus (HPV) 16+ Relapsed/Refractory CancerUnited States
-
Monash UniversityThe Alfred; University of MelbourneRecruitingCancer | Anal Cancer | HPV Infection | HPV | Human Papillomavirus Infection | Men | HPV 16 InfectionAustralia
-
Monash UniversityThe Alfred; University of MelbourneRecruitingCancer | Anal Cancer | HPV Infection | HPV | Human Papillomavirus Infection | Men | HPV 16 InfectionAustralia
-
Teal Health, Inc.Enrolling by invitationHPV Infection | HPV 16 Infection | Hpv | High Risk HPVUnited States
-
Sidney Kimmel Comprehensive Cancer Center at Johns...PapiVax Biotech, Inc.RecruitingHPV 16+ Recurrent or Metastatic CancerUnited States
-
Sinocelltech Ltd.RecruitingHPV Infection Vaccine Safety SCT1000China
-
Ulla Bonde van ZwolUniversity of Southern Denmark; Region of Southern Denmark; MCM Vaccines B.V.Unknown
-
PDS Biotechnology Corp.CompletedHigh-risk HPV Infection and Biopsy-proven CIN1United States
-
Capital Medical UniversityUnknown
Clinical Trials on Comparator: HPV 16 L1 Vaccine
-
GlaxoSmithKlineCompletedInfections, PapillomavirusBelgium, United States
-
National Cancer Institute (NCI)Active, not recruitingHuman Papillomavirus-Related Cervical CarcinomaCosta Rica
-
National Institute for Control of Vaccine and BiologicalsUnknownHuman Papillomavirus (HPV) VaccineVietnam
-
GlaxoSmithKlineCompletedInfections, PapillomavirusGermany, Spain, France
-
GlaxoSmithKlineCompletedInfections, PapillomavirusChina
-
National Cancer Institute (NCI)Active, not recruitingCervical Carcinoma | Human Papillomavirus InfectionCosta Rica
-
GlaxoSmithKlineCompletedInfections, PapillomavirusKorea, Republic of
-
National Cancer Institute (NCI)Bill and Melinda Gates FoundationEnrolling by invitationHuman Papillomavirus Infection | Human Papillomavirus-Related Cervical CarcinomaCosta Rica
-
GlaxoSmithKlineCompletedInfections, PapillomavirusTaiwan, Spain, Germany, Colombia, France, Sweden, Australia, Korea, Republic of, Honduras, Czech Republic, Norway, Panama
-
GlaxoSmithKlineCompletedInfections, PapillomavirusFinland, Russian Federation, Denmark, Greece, Netherlands, Estonia